Catalog Advanced Search
-
Contains 1 Component(s)
Lab automation is constantly evolving. While teams work hard to keep their labs running smoothly today, they must also evaluate and incorporate the emerging automation technologies of tomorrow. In particular, the rise of AI-led scientific discovery may very well turn the entire research process upside down. How can automation teams manage these dynamics and effectively plan for the future? In this webinar from Trilobio, Roya Amini-Naieni, CEO & Co-founder, presents a look at where lab automation is heading and what labs can do to build towards that future. Additionally, with a focus on the practical questions that matter most to the hardware, software, AI, and people of the biology lab. Hardware: Making balanced investments that support today’s experiments while enabling long-term scale. Software: Ensuring devices stay connected across a growing ecosystem of tools and data. AI: Where do you let AI drive your lab, from data analysis to protocol design, and where human expertise remains essential People: How roles will evolve, and how to free up time for training and higher-value work.
Lab automation is constantly evolving. While teams work hard to keep their labs running smoothly today, they must also evaluate and incorporate the emerging automation technologies of tomorrow. In particular, the rise of AI-led scientific discovery may very well turn the entire research process upside down. How can automation teams manage these dynamics and effectively plan for the future?In this webinar from Trilobio, Roya Amini-Naieni, CEO & Co-founder, presents a look at where lab automation is heading and what labs can do to build towards that future. Additionally, with a focus on the practical questions that matter most to the hardware, software, AI, and people of the biology lab.
- Hardware: Making balanced investments that support today’s experiments while enabling long-term scale.
- Software: Ensuring devices stay connected across a growing ecosystem of tools and data.
- AI: Where do you let AI drive your lab, from data analysis to protocol design, and where human expertise remains essential
- People: How roles will evolve, and how to free up time for training and higher-value work.
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
Contains 1 Component(s)
In this insightful webinar from Roylan Developments, Stuart Naylor, Managing Director, presents storage and compound-handling practices and benefits to support your research.
In this insightful webinar from Roylan Developments, Stuart Naylor, Managing Director, presents storage and compound-handling practices and benefits to support your research.
The storage of small molecule compound collections (in DMSO) in a nitrogen storage environment can offer many benefits, such as avoiding the need to freeze compounds and maintaining compound concentrations and activity levels by keeping DMSO free of moisture.
Additionally, it is now possible to dehydrate DMSO compound solutions to recover ECHO® microplates. The benefits are numerous, including a significant extension of the shelf life of DMSO-solubilized samples stored in microplates, thereby reducing operational costs. This webinar examines these storage and compound-handling practices and present their benefits.
Key learning points:- A technique for long-term, room temperature, high-quality storage of chemical libraries solubilized in DMSO
- Technique for recovery of ECHO®-plated test libraries to a >95% DMSO concentration
- Unique characteristics of an easy-to-use, small-footprint, scalable, and validated hardware solution
- How to eliminate moisture in your compound libraries and retain/reuse moisture-laden ECHO® plates.
This webinar is essential for scientists and lab managers focused on high-throughput screening, compound management, and assay development.
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
Contains 1 Component(s)
This TIE explores how digital twins are transforming laboratory design and automation - where they work, where they don’t, and what’s coming next. Speaker: Sura Hadi, E Tech Group
This TIE explores how digital twins are transforming laboratory design and automation - where they work, where they don’t, and what’s coming next. Speaker: Sura Hadi, E Tech Group
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register
-
Contains 31 Component(s) Recorded On: 04/16/2025
SLAS Meet-Ups allows you to stay connected to the latest research and opportunities happening within the SLAS global community. Meet-Ups include the following: SLAS Technology Idea Exchange, the SLAS Get Ahead series, Special Interest Group Science Circle series and any in-person or virtual Regional Community Meet-Ups.
SLAS Meet-Ups allows you to stay connected to the latest research and opportunities happening within the SLAS global community. Meet-Ups include the following: SLAS Technology Idea Exchange, the SLAS Get Ahead series, Special Interest Group Science Circle series and any in-person or virtual Regional Community Meet-Ups.
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
This TIE discusses the challenges and opportunities of creating standardized automated workflows for single-cell analysis and highlighted innovations that bridge the gap from biopsy to clinically relevant insights. Speakers: Stefan Scheuermann, Fraunhofer IPA Mario Nikolas Graeve, Fraunhofer IPA
This TIE discusses the challenges and opportunities of creating standardized automated workflows for single-cell analysis and highlighted innovations that bridge the gap from biopsy to clinically relevant insights. Speakers: Stefan Scheuermann, Fraunhofer IPA Mario Nikolas Graeve, Fraunhofer IPA
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
Join Rui Campos, VP of Product, and Mike Asham, MS, Head of Presales from Automata, to explore how connecting the bench to the cloud can transform lab operations—from scaling throughput to improving data quality and compliance.
Join Rui Campos, VP of Product, and Mike Asham, MS, Head of Presales from Automata, to explore how connecting the bench to the cloud can transform lab operations—from scaling throughput to improving data quality and compliance.
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
This SLAS Technology Idea Exchange features three companies from the inaugural SLAS NexusXp People's Choice Award-winning collaboration: "TEST," - The Future of Drug Discovery: DeepCure's AI and Robotics Driven Pipeline. DeepCure is accelerating drug discovery through AI, robotics and advanced informatics. A fully integrated hardware and software solution was deployed to synthesize, purify and advance 5,000 to 10,000 new compounds every month through the development pipeline. Design-Make-Test-Analyze (DMTA) was fully automated and increased laboratory efficiency by orders of magnitude. This was accomplished through deep collaboration between DeepCure, Waters and Biosero. Representing TEST for this T.I.E. will be Thrasyvoulos Karydis (DeepCure), Dustin Whitson (Biosero), and Andrew Leightner (Waters), with Hayley Dyer (Biosero) and SLAS Scientific Manager Emily Yamasaki, Ph.D., serving as moderators.
This SLAS Technology Idea Exchange features three companies from the inaugural SLAS NexusXp People's Choice Award-winning collaboration: "TEST," - The Future of Drug Discovery: DeepCure's AI and Robotics Driven Pipeline.
DeepCure is accelerating drug discovery through AI, robotics and advanced informatics. A fully integrated hardware and software solution was deployed to synthesize, purify and advance 5,000 to 10,000 new compounds every month through the development pipeline. Design-Make-Test-Analyze (DMTA) was fully automated and increased laboratory efficiency by orders of magnitude. This was accomplished through deep collaboration between DeepCure, Waters and Biosero.
Representing TEST for this T.I.E. will be Thrasyvoulos Karydis (DeepCure), Dustin Whitson (Biosero), and Andrew Leightner (Waters), with Hayley Dyer (Biosero) and SLAS Scientific Manager Emily Yamasaki, Ph.D., serving as moderators.
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
Jesse Boehm, PhD Over the past decade, we have witnessed a revolution in cancer precision medicine which is now enabling the delivery of targeted, chemotherapeutic and immunotherapeutic agents to patients whose tumors harbor molecular features predicting key vulnerabilities. To ensure that each patient with a common or rare cancer stands to benefit from these advances, equally powerful functional genomics technologies deployed at scale are becoming essential to both accelerate the nomination of novel targets for therapeutic development and to validate molecular predictions encoded by the complex molecular makeup of a given patient’s tumor. Dr. Boehm will report on the state of the precision functional genomics field, including his work on the Cancer Dependency Map and the international Human Cancer Models Initiative and describe ongoing work in the lab to apply single cell genomics technologies to readout the perturbation of heterogenous human tumor tissues on clinically meaningful timeframes. To drive these and other solutions, Dr. Boehm will describe the emerging shift in our nation towards team science driven by the pillars of “radical collaboration” and provide examples of how Break Through Cancer TeamLabs are collaborating urgently to template new models and solutions to benefit patients even faster.
Jesse Boehm, PhD
Over the past decade, we have witnessed a revolution in cancer precision medicine which is now enabling the delivery of targeted, chemotherapeutic and immunotherapeutic agents to patients whose tumors harbor molecular features predicting key vulnerabilities. To ensure that each patient with a common or rare cancer stands to benefit from these advances, equally powerful functional genomics technologies deployed at scale are becoming essential to both accelerate the nomination of novel targets for therapeutic development and to validate molecular predictions encoded by the complex molecular makeup of a given patient’s tumor. Dr. Boehm will report on the state of the precision functional genomics field, including his work on the Cancer Dependency Map and the international Human Cancer Models Initiative and describe ongoing work in the lab to apply single cell genomics technologies to readout the perturbation of heterogenous human tumor tissues on clinically meaningful timeframes. To drive these and other solutions, Dr. Boehm will describe the emerging shift in our nation towards team science driven by the pillars of “radical collaboration” and provide examples of how Break Through Cancer TeamLabs are collaborating urgently to template new models and solutions to benefit patients even faster.-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
Ahmar U. Zaidi, MD Sickle cell disease represents a microcosm of how lack of equity and compassion can influence science and care of those affected. In this talk, Dr. Zaidi will discuss the lessons we can take from this disease space to apply to other areas of healthcare.
Ahmar U. Zaidi, MD
Sickle cell disease represents a microcosm of how lack of equity and compassion can influence science and care of those affected. In this talk, Dr. Zaidi will discuss the lessons we can take from this disease space to apply to other areas of healthcare.-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
This session is led by Len Glass, Senior Associate Scientist, FMC Corporation and Christopher Keim, Head Process Automation, Food Brewer. The discussion will cover the three main topics about Agriculture Research and Development work. These topics include BioPharma similarities and differences, the two main Agriculture industry components between pesticides and GMOs, and current trends for the Agriculture industry.
This SLAS Technology Idea Exchange is led by Len Glass, Senior Associate Scientist, FMC Corporation and Christopher Keim, Head Process Automation, Food Brewer. The discussion will cover the three main topics about Agriculture Research and Development work. These topics include BioPharma similarities and differences, the two main Agriculture industry components between pesticides and GMOs, and current trends for the Agriculture industry.
-
You must log in to register
- Non-member - Free!
- Member - Free!
- Student Member - Free!
- Lab Member - Free!
- More Information
-
You must log in to register